{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(21)"],"submitter":["Xu C"],"pubmed_abstract":["Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first \"tumor agnostic\" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor trea"],"journal":["Thoracic cancer"],"pagination":["3084-3097"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9626341"],"repository":["biostudies-literature"],"pubmed_title":["Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China."],"pmcid":["PMC9626341"],"pubmed_authors":["Shi L","Lin R","Lan F","Si L","Zhang J","Hu X","Lin X","Zhang S","Zhang R","Shi X","Zhan P","Wan B","Jin G","Guo H","Xue J","Zhang C","Chu Q","Xu C","Yuan J","Yuan D","Feng H","Lin G","Pu X","Pang F","Lei L","Meng R","Zhu Z","Zhu Y","Tang C","Yu G","Han Y","Yu J","Wei Q","Zhou C","Yu Z","Wei J","Zhou J","Lv D","Ye M","Lv T","Dai E","Wu J","Qiu H","Wu L","Dong X","Huang J","Wang B","Lu Y","Wang D","Wang F","Du Y","Wang G","Wang H","Wang K","Wang L","Ge R","Rao C","Wang Q","Sun P","Ou J","Wang W","Chen Y","Chen X","Wang X","Kang J","Wang Z","Xia F","Xie Y","Yang L","Yang N","Zhong W","Yao W","Li W","Min L","Li X","Li Y","Li Z","Liu H","Liu J","Ma S","Cai J","Jia H","Miao L","Niu X","Liu W","Jiang Z","Liu Z","Yao Y","Song Z","Song Y","Pan W","Fang Y","Luo J","Fang W","Zhang Y","Zhang X","Liu A","Fang M","Cai X"],"additional_accession":[]},"is_claimable":false,"name":"Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.","description":"Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first \"tumor agnostic\" drugs approved for pan-cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second-generation drugs designed to overcome first-generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor trea","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T20:50:01.283Z","creation":"2025-02-19T00:31:53.349Z"},"accession":"S-EPMC9626341","cross_references":{"pubmed":["36127731"],"doi":["10.1111/1759-7714.14644"]}}